SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30

$2.96−0.12 (-3.90%)

Close on Nov 13, 2026Market cap $269.32MP/E –Yield –

SAB Biotherapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

SAB Biotherapeutics's total debt was $0 at Dec 31, 2024. For fiscal 2024 it was $0. The highest annual figure on record is $541.64K in fiscal 2022.

Period	Period end	Value	Change
FY2024	Dec 31, 2024	$0	–
FY2023	Dec 31, 2023	$0	-100.0%
FY2022	Dec 31, 2022	$541.64K	–
FY2021	Dec 31, 2021	$0	-100.0%
FY2020	Dec 31, 2020	$172.04K	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q4 FY2024	Dec 31, 2024	$0	–
Q4 FY2023	Dec 31, 2023	$0	–
Q4 FY2022	Dec 31, 2022	$541.64K	+214.8%
Q2 FY2022	Jun 30, 2022	$0	–
Q1 FY2022	Mar 31, 2022	$0	–
Q4 FY2021	Dec 31, 2021	$0	–
Q4 FY2020	Dec 31, 2020	$172.04K	–

Parsed from the XBRL in SAB Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5.67 reverse split on Mar 29, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SABS.

Revenue growth-100.0% · median 7.1%

Advertisement
300 × 250

See a number that looks wrong?